Placebo for TransCon CNP, TransCon CNP 3.9 mg CNP-38/vial, Navepegritide 2.8 mg CNP(89-126), Navepegritide 1.3 mg CNP(89-126)
ASND0030
Phase 2 small_molecule active
Quick answer
Placebo for TransCon CNP, TransCon CNP 3.9 mg CNP-38/vial, Navepegritide 2.8 mg CNP(89-126), Navepegritide 1.3 mg CNP(89-126) for Achondroplasia in Children and Adolescents is a Phase 2 program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Achondroplasia in Children and Adolescents
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active